Cytokinetics, Inc. (CYTK)
| Market Cap | 1.43B |
| Revenue (ttm) | 54.32M |
| Net Income (ttm) | -114.00M |
| Shares Out | 68.28M |
| EPS (ttm) | -1.85 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 21 |
| Last Price | $20.09 |
| Previous Close | $19.98 |
| Change ($) | 0.11 |
| Change (%) | 0.55% |
| Day's Open | 20.01 |
| Day's Range | 19.20 - 20.27 |
| Day's Volume | 627,874 |
| 52-Week Range | 8.75 - 28.96 |
Company Earns $2.5 Million Milestone Payment from Ji Xing Pharmaceuticals Company Earns $2.5 Million Milestone Payment from Ji Xing Pharmaceuticals
SOUTH SAN FRANCISCO, Calif., Jan. 11, 2021 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the U.S. Food and Drug Administration (FDA) has granted orphan dru...
SOUTH SAN FRANCISCO, Calif., Jan. 06, 2021 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is schedule...
Company is Planning Regulatory Interactions in 2021 to Discuss Results of GALACTIC-HF and Expects to Evaluate Strategic Options for Co-Commercialization and Licensing Company is Planning Regul...
Additional Data from FORTITUDE-ALS Support Rationale and Design for COURAGE-ALS, A Planned Phase 3 Clinical Trial of Reldesemtiv in Patients with ALS Additional Data from FORTITUDE-ALS Support...
Interim Analysis of Data from Cohort 1 Demonstrate Substantial Effects of CK-274 to Reduce LVOT Gradient in Patients with Obstructive Hypertrophic Cardiomyopathy with No Dose Interruptions Due...
Supplemental Analyses of Primary Composite Endpoint Further Demonstrate Effect of Omecamtiv Mecarbil In Patie nts with Lower Ejection Fraction
SOUTH SAN FRANCISCO, Calif., Dec. 03, 2020 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced three poster presentations at the 31st International Symposium on ALS/M...
SOUTH SAN FRANCISCO, Calif., Dec. 01, 2020 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on November 30, 2020 it granted stock options to purchase an aggre...
Data from Supplemental Analyses to be Shared at Clinical Trials Think Tank Meeting Data from Supplemental Analyses to be Shared at Clinical Trials Think Tank Meeting
In this article we present the list of Top 10 Healthcare Stocks for the Future. Click to skip ahead and see the Top 5 Healthcare Stocks for the Future .
SOUTH SAN FRANCISCO, Calif., Nov. 24, 2020 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq:CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled...
Amgen (AMGN) will terminate the collaboration with Cytokinetics and transition development and commercialization rights for omecamtiv mecarbil and AMG 594 to the latter.
Company Committed to Advancing Omecamtiv Mecarbil with Initial Focus on Preparation s for Regulatory Interaction s Following Positive Results of GALACTIC-HF
TipRanks analyst ranking service pinpoints Wall Street's best-performing stocks, like Amazon and Yelp.
Appointment Strengthens Commercial, Market Access and Specialty Sales Expertise as Company Advances Pipeline Toward Potential Commercialization Appointment Strengthens Commercial, Market Acces...
SOUTH SAN FRANCISCO, Calif., Nov. 16, 2020 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that new findings from analyses of claims data and electronic health re...
New Findings from Studies of Cardiac Myosin Inhibitors in Animal Models of Hypertrophic Cardiomyopathy and Heart Failure with Preserved Ejection Fraction New Findings from Studies of Cardiac M...
Trial Met Primary Composite Endpoint of Reduction in Heart Failure Events or Cardiovascular Death; Did Not Meet Secondary Endpoints Including Reduction in Cardiovascular Death
SOUTH SAN FRANCISCO, Calif., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on October 30, 2020 it granted stock options to purchase an aggreg...
Primary Results from GALACTIC-HF to be Presented in Late Breaking Clinical Trial Session
Cytokinetics, Inc. (CYTK) CEO Robert Blum on Q3 2020 Results - Earnings Call Transcript
Cytokinetics (CYTK) delivered earnings and revenue surprises of 91.53% and 997.05%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Cytokinetics (CYTK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Cytokinetics (CYTK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
SOUTH SAN FRANCISCO, Calif., Oct. 21, 2020 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is scheduled to report third quarter results on November 4, 202...
Amgen Inc. (NASDAQ:AMGN) and its partner, Cytokinetics Inc. (NASDAQ:CYTK), took a punch to the gut last week when the heart drug they were collaborating on failed to meet expectations. Thousan...
Amgen and Cytokinetics disappointed with key Phase 3, final-stage trial results for a heart treatment that aims to reduce cardiovascular death; sending CYTK crashing and AMGN down hard. The po...
Trial Met Primary Composite Endpoint of Reduction in Cardiovascular Death or Heart Failure Events
Cytokinetics (CYTK) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.
Real-World Population Representative of P atients Enrolled in GALACTIC-HF I ndicate a H igh- N eed, H igh- R isk P opulation with Heart Failure
Heart Failure Patients in Phase 3 Clinical Trial of Omecamtiv Mecarbil Are at High Risk of Cardiovascular Events and Symptom Burden
Investors need to pay close attention to Cytokinetics (CYTK) stock based on the movements in the options market lately.
SOUTH SAN FRANCISCO, Calif., Sept. 24, 2020 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that new data will be presented at the Heart Failure Society of Amer...
Grant s Suppor t Community Engagement for Patient Advocacy Organization s Focused on Cardiovascular and Neuromuscular Diseases
Company Advances Second Cardiac Myosin Inhibitor Company Advances Second Cardiac Myosin Inhibitor
Trial Proceeding Toward Conclusion, Topline Results Expected in Q4 2020 Trial Proceeding Toward Conclusion, Topline Results Expected in Q4 2020
ELK GROVE VILLAGE, Ill. and SOUTH SAN FRANCISCO, Calif., Aug. 26, 2020 (GLOBE NEWSWIRE) -- Cure SMA and Cytokinetics (Nasdaq:CYTK) today announced the renewal of their partnership to increas...
Company Makes Long-term Commitment to Outcomes Research in HCM Company Makes Long-term Commitment to Outcomes Research in HCM
Cytokinetics, Incorporated's (CYTK) CEO Robert Blum on Q2 2020 Results - Earnings Call Transcript
Top-line Results from GALACTIC-HF Expected in Q4 2020
Cytokinetics (CYTK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
SOUTH SAN FRANCISCO, Calif., July 23, 2020 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is scheduled to report second quarter results on August 6, 20...
SOUTH SAN FRANCISCO, Calif., July 21, 2020 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq:CYTK) today announced the closing of its previously announced underwritten public offering o...
SOUTH SAN FRANCISCO, Calif., July 16, 2020 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq:CYTK) today announced the pricing of an underwritten public offering of 7,291,667 shares of ...
SOUTH SAN FRANCISCO, Calif., July 15, 2020 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq:CYTK) today announced plans to offer, subject to market and other conditions, $150,000,000 o...
Topline Results from GALACTIC-HF, Phase 3 Clinical Trial of Omecamtiv Mecarbil, Cardiac Myosin Activator, Expected in Q4
NEW YORK--(BUSINESS WIRE)--Headline of release should read: RTW Investments, LP, Ji Xing Pharmaceuticals and Cytokinetics Enter Into Strategic Financing Collaboration to Support the Developmen...
$250 Million in Committed Capital to Cytokinetics; Additional $200 Million in Development and Commercialization Milestone Payments
SOUTH SAN FRANCISCO, Calif., July 13, 2020 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is participating in the launch of Kainomyx, Inc., a new bioph...
About CYTK
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company is developing small molecule drug candidates primarily engineered to increase muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure; and reldesemtiv, a novel fast skeletal muscle troponin activator, wh... [Read more...]
| Industry Biotechnology | IPO Date Apr 29, 2004 |
| CEO Robert Blum | Employees 156 |
| Stock Exchange NASDAQ | Ticker Symbol CYTK |
Financial Performance
In 2019, Cytokinetics's revenue was $26.87 million, a decrease of -14.71% compared to the previous year's $31.50 million. Losses were -$121.69 million, 14.5% more than in 2018.
Analyst Forecasts
According to 9 analysts, the average rating for Cytokinetics stock is "Buy." The 12-month stock price forecast is 27.00, which is an increase of 34.40% from the latest price.